<div>Our daughter Phoebe was diagnosed in February of last year with a rare and life-altering condition called Alexander disease, a progressive neurological disorder caused by a mutation in the GFAP gene. This disease affects the brain’s support cells and can lead to challenges with mobility, coordination, speech, and overall development. The diagnosis was heartbreaking—but we believe God has a purpose in every detail of her life, and we are committed to doing everything we can to give her the best possible chance.
</div>
<div><br />
</div>
<div>Nearly a year into this journey, Phoebe has largely plateaued developmentally. We are thankful that the supplement and supportive care plan we’ve put in place appears to be helping stabilize her and prevent further decline. However, meaningful improvement is unlikely without a treatment that directly targets the underlying disease process.
</div>
<div><br />
</div>
<div>For the past several months, we have been pursuing exosome-based supportive therapy, administered under the care of a trusted provider. While this therapy does not correct the genetic mutation, it has been part of our effort to reduce inflammation, support brain health, and preserve function. We plan to continue this therapy as long as it remains helpful and appropriate.
</div>
<div><br />
</div>
<div>At the same time, we are now actively pursuing access to zilganersen, an investigational medication developed by Ionis Pharmaceuticals that is designed to target the genetic mechanism responsible for Alexander disease. This medication is not yet FDA-approved and is being made available only through a limited Expanded Access Program coordinated through Children’s Hospital of Philadelphia (CHOP). The process involves regulatory approvals, baseline testing, and careful medical oversight, and participation is not guaranteed. We are currently completing required evaluations and preparing as best we can while awaiting next steps.
</div>
<div><br />
</div>
<div>Because Alexander disease has no approved cure, we are pursuing every responsible avenue that may help Phoebe—supportive, investigational, or potentially disease-modifying—while remaining grounded, prayerful, and medically guided.
</div>
<div><br />
</div>
<div>All funds raised through this campaign will go toward any and all efforts to improve Phoebe’s quality of life or slow disease progression, including but not limited to:
</div>
<div>	•	supportive therapies and supplements
</div>
<div>	•	investigational or expanded-access medications
</div>
<div>	•	medical testing and evaluations
</div>
<div>	•	travel and lodging related to specialized care
</div>
<div>	•	unforeseen medical expenses connected to her treatment journey
</div>
<div><br />
</div>
<div>We believe in a miracle-working God—and whether that miracle comes through medical research, compassionate community, or quiet faithfulness in the waiting, we are trusting Him each step of the way.
</div>
<div><br />
</div>
<div>If you feel led to give, share, or pray, thank you for walking alongside us. Your support means more than we can put into words.
</div>
<div><br />
</div>
<div>With gratitude and hope,
</div>
<div>Rob &amp; Ashley Caudill
</div>
<div><br />
</div>

Anonymous

Jim Schultheis

Robert P Frye

Vicki Rush

Nicole Lutchka

Kalee Reynolds

Sydney Principato

michelle umbarger

Todd Bowditch

Hope for Phoebe: Help Us Fight Alexander Disease

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

currencyCode

Money Box Donation List Prompt Experiment Audience

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

NPO upsell education category

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

NPO recommendations prod

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

categoryGroup

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

NPO upsell animals category

NPO upsell disaster relief category

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

NPO upsell essential needs category

NPO upsell medical category

userCurrencyCode

Localized Currency

NPO upsell cancer category

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Hope for Phoebe: Help Us Fight Alexander Disease

Still $43,288 to go. Help us build momentum.